ABSTRACT
Abstract Introduction: Keloids and hypertrophic scars are dermal fibro-proliferative disorders unique to humans. Their treatment is a true challenge with multiple options, but not all the time with good results. Unfortunatelythis problem is not uncommon in patients with history of burn injury. Aim: To evaluate use of verapamil andpressure garments in patients with hypertrophic or keloid scar caused by burn injury. methods: We includedpatients with a hypertrophic or keloid scar caused by burn injury that report non-response to treatment withpressure garment. The pathologic scars were evaluated by serial photographic records, Vancouver and Posasscales. The scales of Vancouver and Posas were compared with t Student. Results: We included 13 scars in11 patients. Four scars were located in the legs, 4 in the arms, 4 in the face-neck and 1 in the abdomen. Thedose of verapamil was calculated 0.03 mg per kg. Injections were scheduled every 7 to 10 days until complete 6 sessions. Taking in count Posas scale, patients referred improvement in pigmentation (0.01), thickness(0.005), pliability (0.01), pruritus (0.003) and irregular surface (0.004). In the Vancouver scale the observers mentioned improvement in elevation (0.008), pigmentation (0.014), vascularity (0.022) and flexibility (0.014).No adverse effects were found in verapamil injection. Conclusion: Verapamil was useful in conjunction withpressure garment to improve the condition of the keloid and hypertrophic scar caused by burn.
Resumen Introducción: La cicatriz queloide o la cicatriz hipertrófica son desórdenes fibro-proliferativos únicos de los humanos, cuyo tratamiento representa un reto en donde existen pocas opciones con buenos resultados.Objetivo: Evaluar el uso de verapamilo y las prendas de compresión en pacientes con cicatrización patológicacomo consecuencia de quemadura. material y método: Incluimos pacientes con cicatrización patológica,ya sea queloide o hipertrófica, causada por quemadura que mencionaron no haber tenido beneficio con el usode prendas de compresión. La cicatriz fue evaluada con fotografías seriadas, escala de Vancouver y Posas.Los resultados fueron comparados con la prueba de t de Student. Resultados: Incluimos 13 cicatrices en 11pacientes. La localización de las cicatrices fue en brazos 4, piernas 4, cara y cuello 1, y abdomen 1. La dosisde verapamilo se calculó a 0,03 mg por kg. Las inyecciones se aplicaron intralesionales y se administraroncada 7 a 10 días hasta completar 6 sesiones. Encontramos mejoría en los siguientes parámetros de la escalade Posas: pigmentación (0,01), pliabilidad (0,01), endurecimiento o grosor (0,005), prurito (0,003) e irregular (0,004). En la escala de Vancouver elevación (0,008), pigmentación (0,014), vascularidad (0,022) yflexibilidad (0,014). No encontramos efectos adversos con la administración de verapamilo. Conclusión: Elverapamilo fue útil en conjunto con las prendas de compresión para mejorar las condiciones de la cicatrizqueloide e hipertrófica causadas por lesiones por quemadura.
Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Verapamil/therapeutic use , Cicatrix, Hypertrophic/therapy , Compression Bandages , Keloid/therapy , Burns/complications , Prospective Studies , Cicatrix, Hypertrophic/etiology , Keloid/etiologyABSTRACT
Liver fibrosis is the common response to chronic liver injury, ultimately leading to cirrhosis and its complications: portal hypertension, liver failure, hepatic encephalopathy, and hepatocellular carcinoma and others. Efficient and well-tolerated antifibrotic drugs are still lacking, and current treatment of hepatic fibrosis is limited to withdrawal of the noxious agent. Efforts over the past decade have mainly focused on fibrogenic cells generating the scarring response, although promising data on inhibition of parenchymal injury or reduction of liver inflammation have also been obtained. A large number of approaches have been validated in culture studies and in animal models, and several clinical trials are underway or anticipated for a growing number of molecules. This review highlight recent advances in the molecular mechanisms of liver fibrosis and discusses mechanistically based strategies that have recently emerged.